Remimazolam besylate for anesthesia and intensive care sedation in patients with malignancy: A narrative review of pharmacology, immune effects and clinical evidence
Remimazolam besylate for anesthesia and intensive care sedation in patients with malignancy: A narrative review of pharmacology, immune effects and clinical evidence. // JCA Advances. – URL: https://www.sciencedirect.com/science/article/pii/S295055342600081X?dgcid=rss_sd_all
Remimazolam besylate for anesthesia and intensive care sedation in patients with malignancy: A narrative review of pharmacology, immune effects and clinical evidence. JCA Advances. https://www.sciencedirect.com/science/article/pii/S295055342600081X?dgcid=rss_sd_all
“Remimazolam besylate for anesthesia and intensive care sedation in patients with malignancy: A narrative review of pharmacology, immune effects and clinical evidence.” JCA Advances.
@article{article51007,
title = {Remimazolam besylate for anesthesia and intensive care sedation in patients with malignancy: A narrative review of pharmacology, immune effects and clinical evidence},
journal = {JCA Advances},
url = {https://www.sciencedirect.com/science/article/pii/S295055342600081X?dgcid=rss_sd_all}
}
ABSTRACT Background For half the world's population, headaches represent a major health burden that cripples productivity and mental well‐being. While newer CGRP‐targeted drugs have shown promise for migraines, less is known about how...